Santino Minichillo

609 total citations
17 papers, 347 citations indexed

About

Santino Minichillo is a scholar working on Genetics, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Santino Minichillo has authored 17 papers receiving a total of 347 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Genetics, 11 papers in Pulmonary and Respiratory Medicine and 5 papers in Oncology. Recurrent topics in Santino Minichillo's work include Glioma Diagnosis and Treatment (12 papers), Brain Metastases and Treatment (6 papers) and Meningioma and schwannoma management (5 papers). Santino Minichillo is often cited by papers focused on Glioma Diagnosis and Treatment (12 papers), Brain Metastases and Treatment (6 papers) and Meningioma and schwannoma management (5 papers). Santino Minichillo collaborates with scholars based in Italy and United States. Santino Minichillo's co-authors include Alba A. Brandes, Enrico Franceschi, Lucia Del Mastro, Irene De Santo, Lorenzo Gerratana, Mario Giuliano, Grazia Arpino, Debora Basile, Michelino De Laurentiis and Andrea Coinu and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and European Journal of Cancer.

In The Last Decade

Santino Minichillo

17 papers receiving 344 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Santino Minichillo Italy 9 160 137 120 110 84 17 347
María Ángeles Vaz Salgado Spain 9 125 0.8× 62 0.5× 101 0.8× 122 1.1× 81 1.0× 44 354
Joseph W. Po Australia 12 155 1.0× 140 1.0× 60 0.5× 72 0.7× 112 1.3× 15 320
Ruizhe Zhu China 9 71 0.4× 140 1.0× 50 0.4× 86 0.8× 168 2.0× 12 364
Anja Bukovac Croatia 9 92 0.6× 89 0.6× 52 0.4× 36 0.3× 179 2.1× 15 320
Víctor Albarrán Spain 10 155 1.0× 36 0.3× 74 0.6× 52 0.5× 68 0.8× 17 284
Estelle Daudigeos‐Dubus France 11 102 0.6× 72 0.5× 89 0.7× 58 0.5× 161 1.9× 19 332
Daniela Boggiani Italy 9 195 1.2× 80 0.6× 123 1.0× 17 0.2× 81 1.0× 15 279
Mianfu Cao China 12 141 0.9× 116 0.8× 91 0.8× 82 0.7× 193 2.3× 17 436
Xuejun Zhang China 10 72 0.5× 50 0.4× 63 0.5× 54 0.5× 133 1.6× 38 310

Countries citing papers authored by Santino Minichillo

Since Specialization
Citations

This map shows the geographic impact of Santino Minichillo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Santino Minichillo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Santino Minichillo more than expected).

Fields of papers citing papers by Santino Minichillo

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Santino Minichillo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Santino Minichillo. The network helps show where Santino Minichillo may publish in the future.

Co-authorship network of co-authors of Santino Minichillo

This figure shows the co-authorship network connecting the top 25 collaborators of Santino Minichillo. A scholar is included among the top collaborators of Santino Minichillo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Santino Minichillo. Santino Minichillo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Conté, Pierfranco, Giancarlo Bisagni, Federico Piacentini, et al.. (2023). Nine-weeks versus one-year trastuzumab for early-stage HER2+ breast cancer: 10-year update of the Short-HER phase III randomized trial.. Journal of Clinical Oncology. 41(17_suppl). LBA637–LBA637. 2 indexed citations
2.
Nunno, Vincenzo Di, Enrico Franceschi, Alicia Tosoni, et al.. (2021). Is Molecular Tailored-Therapy Changing the Paradigm for CNS Metastases in Breast Cancer?. Clinical Drug Investigation. 41(9). 757–773. 1 indexed citations
3.
Franceschi, Enrico, Santino Minichillo, Alicia Tosoni, et al.. (2021). Expertise is crucial to prolong survival in average risk medulloblastoma: long-term results of a retrospective study. Tumori Journal. 108(4). 331–337. 2 indexed citations
4.
Franceschi, Enrico, Santino Minichillo, Antonella Mura, et al.. (2020). Adjuvant chemotherapy in average-risk adult medulloblastoma patients improves survival: a long term study. BMC Cancer. 20(1). 755–755. 16 indexed citations
5.
Nunno, Vincenzo Di, Enrico Franceschi, Alicia Tosoni, et al.. (2020). Treatment of recurrent glioblastoma: state-of-the-art and future perspectives. Expert Review of Anticancer Therapy. 20(9). 785–795. 24 indexed citations
6.
Franceschi, Enrico, Alicia Tosoni, Stefania Bartolini, et al.. (2020). Histopathological grading affects survival in patients with IDH-mutant grade II and grade III diffuse gliomas. European Journal of Cancer. 137. 10–17. 35 indexed citations
7.
Franceschi, Enrico, Alicia Tosoni, Dario de Biase, et al.. (2019). Postsurgical Approaches in Low-Grade Oligodendroglioma: Is Chemotherapy Alone Still an Option?. The Oncologist. 24(5). 664–670. 4 indexed citations
8.
Lamberti, Giuseppe, Enrico Franceschi, Alicia Tosoni, et al.. (2019). Adjuvant chemotherapy to improve survival in average-risk adult medulloblastoma patients: Long-term results.. Journal of Clinical Oncology. 37(15_suppl). 2037–2037. 1 indexed citations
9.
Franceschi, Enrico, Giuseppe Lamberti, Alexandro Paccapelo, et al.. (2018). Third-line therapy in recurrent glioblastoma: is it another chance for bevacizumab?. Journal of Neuro-Oncology. 139(2). 383–388. 12 indexed citations
10.
Gerratana, Lorenzo, Debora Basile, Giuseppe Buono, et al.. (2018). Androgen receptor in triple negative breast cancer: A potential target for the targetless subtype. Cancer Treatment Reviews. 68. 102–110. 187 indexed citations
11.
Franceschi, Enrico, Giuseppe Lamberti, Michela Visani, et al.. (2018). Temozolomide Rechallenge in Recurrent Glioblastoma: When is it Useful?. Future Oncology. 14(11). 1063–1069. 13 indexed citations
12.
Franceschi, Enrico, Santino Minichillo, & Alba A. Brandes. (2017). Pharmacotherapy of Glioblastoma: Established Treatments and Emerging Concepts. CNS Drugs. 31(8). 675–684. 22 indexed citations
13.
Minichillo, Santino, Enrico Franceschi, Antonella Mura, et al.. (2017). The role of treatments in IDH mutant molecular astrocytomas. Annals of Oncology. 28. vi76–vi76. 1 indexed citations
14.
Minichillo, Santino, Ilaria Gallelli, Daniela Rubino, et al.. (2017). Trastuzumab resumption after extremely severe cardiotoxicity in metastatic breast cancer patient: a case report. BMC Cancer. 17(1). 722–722. 5 indexed citations
15.
Franceschi, Enrico, Dario de Biase, Alexandro Paccapelo, et al.. (2017). Low grade glioma patients with IDH mutation and 1p19q codeletion: To treat or not to treat?. Journal of Clinical Oncology. 35(15_suppl). 2017–2017. 8 indexed citations
16.
Minichillo, Santino, Maria A. Pantaleo, Margherita Nannini, et al.. (2015). Efficacy of weekly docetaxel in locally advanced cardiac angiosarcoma. BMC Research Notes. 8(1). 325–325. 13 indexed citations
17.
Re, Marzia Del, Marta Schirripa, Angela Michelucci, et al.. (2012). Results of a comprehensive pharmacogenetic analysis of dihydropyrimidine dehydrogenase in patients treated with fluoropyrimidines and patterns of polymorphisms partially related to treatment tolerability.. Journal of Clinical Oncology. 30(15_suppl). e13057–e13057. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by María Ángeles Vaz Salgado Breakdown of academic impact, for papers by Joseph W. Po Breakdown of academic impact, for papers by Ruizhe Zhu Breakdown of academic impact, for papers by Anja Bukovac Breakdown of academic impact, for papers by Víctor Albarrán Breakdown of academic impact, for papers by Estelle Daudigeos‐Dubus Breakdown of academic impact, for papers by Daniela Boggiani Breakdown of academic impact, for papers by Mianfu Cao Breakdown of academic impact, for papers by Xuejun Zhang
Rankless by CCL
2026